Associations - KIT mutation

KIT mutation KIT mutation	Thymic Carcinoma Thymic Carcinoma	KIT mutation KIT mutation	Thymic Carcinoma Thymic Carcinoma	sunitinib Sensitive: A2 - Guideline	sunitinib Sensitive: A2 - Guideline
KIT mutation KIT mutation	Cutaneous Melanoma Cutaneous Melanoma	KIT mutation KIT mutation	Cutaneous Melanoma Cutaneous Melanoma	imatinib Sensitive: A2 - Guideline	imatinib Sensitive: A2 - Guideline
KIT mutation KIT mutation	Gastrointestinal Stromal Tumor GIST	KIT mutation KIT mutation	Gastrointestinal Stromal Tumor GIST	ripretinib Sensitive: B - Late Trials	ripretinib Sensitive: B - Late Trials
KIT mutation KIT mutation	Gastrointestinal Stromal Tumor GIST	KIT mutation KIT mutation	Gastrointestinal Stromal Tumor GIST	TAS-116 Sensitive: B - Late Trials	TAS-116 Sensitive: B - Late Trials
KIT mutation KIT mutation	Gastrointestinal Stromal Tumor GIST	KIT mutation KIT mutation	Gastrointestinal Stromal Tumor GIST	avapritinib Sensitive: C2 – Inclusion Criteria	avapritinib Sensitive: C2 – Inclusion Criteria
KIT mutation KIT mutation	Gastrointestinal Stromal Tumor GIST	KIT mutation KIT mutation	Gastrointestinal Stromal Tumor GIST	imatinib Sensitive: C2 – Inclusion Criteria	imatinib Sensitive: C2 – Inclusion Criteria
KIT mutation KIT mutation	Melanoma Melanoma	KIT mutation KIT mutation	Melanoma Melanoma	imatinib Sensitive: C2 – Inclusion Criteria	imatinib Sensitive: C2 – Inclusion Criteria
KIT mutation KIT mutation	Melanoma Melanoma	KIT mutation KIT mutation	Melanoma Melanoma	sunitinib Sensitive: C2 – Inclusion Criteria	sunitinib Sensitive: C2 – Inclusion Criteria
KIT mutation KIT mutation	Melanoma Melanoma	KIT mutation KIT mutation	Melanoma Melanoma	nivolumab Sensitive: C2 – Inclusion Criteria	nivolumab Sensitive: C2 – Inclusion Criteria
KIT mutation KIT mutation	Gastrointestinal Stromal Tumor GIST	KIT mutation KIT mutation	Gastrointestinal Stromal Tumor GIST	sunitinib + PLX9486 Sensitive: C3 – Early Trials	sunitinib + PLX9486 Sensitive: C3 – Early Trials
KIT mutation KIT mutation	Acute Myelogenous Leukemia AML	KIT mutation KIT mutation	Acute Myelogenous Leukemia AML	LY3009120 Sensitive: C3 – Early Trials	LY3009120 Sensitive: C3 – Early Trials
KIT mutation KIT mutation	Mucosal Melanoma Mucosal Melanoma	KIT mutation KIT mutation	Mucosal Melanoma Mucosal Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
KIT mutation KIT mutation	Acute Myelogenous Leukemia AML	KIT mutation KIT mutation	Acute Myelogenous Leukemia AML	ivosidenib Resistant: C3 – Early Trials	ivosidenib Resistant: C3 – Early Trials
KIT mutation KIT mutation	Mucosal Melanoma Mucosal Melanoma	KIT mutation KIT mutation	Mucosal Melanoma Mucosal Melanoma	temozolomide Sensitive: C3 – Early Trials	temozolomide Sensitive: C3 – Early Trials
KIT mutation KIT mutation	Mucosal Melanoma Mucosal Melanoma	KIT mutation KIT mutation	Mucosal Melanoma Mucosal Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials	cisplatin + dacarbazine Sensitive: C3 – Early Trials
KIT mutation KIT mutation	Cutaneous Melanoma Cutaneous Melanoma	KIT mutation KIT mutation	Cutaneous Melanoma Cutaneous Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
KIT mutation KIT mutation	Melanoma Melanoma	KIT mutation KIT mutation	Melanoma Melanoma	ripretinib Sensitive: C3 – Early Trials	ripretinib Sensitive: C3 – Early Trials
KIT mutation KIT mutation	Gastrointestinal Stromal Tumor GIST	KIT mutation KIT mutation	Gastrointestinal Stromal Tumor GIST	AZD1775 + avapritinib Sensitive: D – Preclinical	AZD1775 + avapritinib Sensitive: D – Preclinical
KIT mutation KIT mutation	Acute Myelogenous Leukemia AML	KIT mutation KIT mutation	Acute Myelogenous Leukemia AML	cabozantinib tablet Sensitive: D – Preclinical	cabozantinib tablet Sensitive: D – Preclinical